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Abstract 
Introduction: H.pylori infection has 
been associated with various gastric 
pathologies and its prevalence varies 
between different countries. Furthermore, 
there is an increasing antibiotic resistance 
and the eradication rates have declined. 
There is clinical and administrative pressure 
as to provide the Rapid Urease Test (RUT) 
result as quickly as possible and ideally 
prior to discharge from the endoscopy unit. 
Results: A total of 542 patients fulfilled 
the inclusion criteria.  The patient`s mean 
age was 54.6 years and 52.4% were female.  
The main clinical indications for an 
Oesophago-Gastro-Duodenoscopy (OGD) 
were dyspepsia (44.7%) and GORD 
(24.5%). The overall positivity rate was 
15% of which 8.7% were early positive and 
6.3% were late positive. Analysis of 
patients’ age with RUT positivity revealed 
that patients above the age of 60 years were 
more likely to have a positive result 
(p=0.013). There was no statistical 
significance between the H.pylori results 
and smoking (p= 0.6). 
In this study, there was a variety of 10 
different eradication regimes prescribed, the 
most popular being the use of a PPI 20mg 
BD + Amoxicillin 1g BD + Clarithromycin 
500mg BD for 10 days (total of 27 cases) 
versus 14 days (23 cases). 
Conclusion: This study demonstrates 
the importance of checking the RUT taken 
at endoscopy at 24 hours as this has given a 
42% increase in the yield for H.pylori. It 
also demonstrates that various regimens are 
used in clinical practice. In view of the 
relatively low prevalence of H.pylori, 
especially amongst young patients, maybe it 
is prime time that treatment of H.pylori is 
specifically managed by culture and 
sensitivity to avoid worsening 
clarithromycin-resistance. 
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• PPI: Proton Pump Inhibitor 
• RUT: Rapid Urease Test  
 
Introduction and Aims 
Helicobacter pylori (H.pylori) is a 
gram-negative bacterium found in the 
stomach of more than 50% of the population 
worldwide.1 It is linked to chronic gastritis, 
gastric and duodenal ulcers and stomach 
cancer.2 Up to 85% of patients infected with 
H.pylori are asymptomatic;3 therefore a 
‘test-and-treat’ approach is adopted and is 
most effective in a population with a high 
prevalence of H.pylori infection (defined as 
a prevalence of more than 20% ), especially 
in patients under the age of 50 years without 
any alarm symptoms.4 There are various 
methods of testing; these can be divided into 
minimally-invasive (blood antibody test, 
stool antigen test or using the carbon urea 
breath test), and invasive (analysis of gastric 
biopsies through Rapid Urease Test (RUT 
test), histology and culture). None of the 
methods are 100% specific and sensitive. 
One of the most commonly used is the RUT 
test upon performing an 
oesophagogastroduodenoscopy (OGD).5 
This gastric biopsy test is based on the 
activity of the H. pylori urease enzyme. This 
splits the urea test reagent to form ammonia. 
Ammonia, being alkaline, increases the pH. 
This is detected by a colour indicator. Tests 
that produce rapid reliable findings have 
been shown to reduce the overall cost of 
management of these patients by decreasing 
the need for telephone calls to be made to 
patients after 24 hours. 
The standard first-line treatment option 
for H.pylori eradication is a 7-10 twice daily 
(b.d.) triple therapy of proton-pump 
inhibitor (PPI) together with amoxicillin and 
clarithromycin or metronidazole.6 
Unfortunately, such a regime is becoming 
increasingly ineffective worldwide due to 
clarithromycin resistance, with data showing 
that eradication rates have declined to less 
than 80% in both the United States and 
Europe.7 
Several alternative regimes for 
eradication have been proposed, including 
the extension of the treatment duration to 10 
or 14 days; using a different PPI; quadruple 
therapy with the use of bismuth with a PPI 
and two antibiotics; concomitant and 
sequential regimes; use of probiotics-
supplemented triple therapy or using other 
antibiotics such as levofloxacin 8-11.  Despite 
such antibiotic regimens, a 100% 
eradication rate is rarely achieved. 13 The 
success of eradication therapy depends on 
patient compliance and bacterial factors 
such as antibiotic resistance.   
Various studies have demonstrated 
different results on the correlation of 
smoking and prevalence of H.pylori 
infection. It is proposed that smoking is 
negatively associated with H.pylori infection 
due to an increase in gastric acidity 
following smoking,9 whilst other studies 
showed a positive relationship in view of 
damage to gastric mucosal protection 10 and 
reduced efficacy of eradication therapy.11-12 
Others studies have demonstrated that there 
is no statistically significant difference in 
the rate of positive infections in relation to 
current or previous smoking status.14 While 
most of the recent studies have concentrated 
on the choice and prescription of antibiotics 
there is minimal recent data on the timing of 
the interpretation of the RUT after an 
oesophago-gastro-duodenoscopy (OGD). 
The primary aims of this study were: 
1. To assess the diagnostic accuracy of the 
RUT by assessing it at 4 hours and 24 
hours.  
2. To determine whether there is a 
correlation between smoking and 
H.pylori infection. 
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3. To identify the different treatment 
regimes prescribed at our local hospital. 
A secondary aim of the study was to 
determine the prevalence of positive 
H.pylori infections among patients 
undergoing an OGD. 
 
Methodology 
This was a prospective study performed 
between January 2016 and July 2016. 
Approval was obtained from the Malta 
University Research Ethics Committee.  
Ninety-five percent (95%) of the 
endoscopists who perform OGD’s at Mater 
Dei Hospital agreed to participate. The 
following data was obtained and entered 
into the database: date of procedure; 
patient`s age; gender; clinical indication; 
RUT; treatment regime prescribed and 
smoking status. The exclusion criteria were: 
(1) patients had already been tested and/or 
treated for H.pylori (2) use of proton pump 
inhibitors in the 2 weeks prior to the test and 
(3) the use of antibiotics in the preceding 4 
weeks. 
The RUT used in each case by all 
endoscopists involved was the Kimberly-
ClarK CLOtest Rapid Urease Test. The test 
was defined as either negative, early positive 
or late positive. 
The patients’ OGD reports were 
checked on the same day of the procedure 
and the following day by two investigators. 
If the RUT test showed a colour change up 
to 4 hours after the procedure, it was marked 
as “early positive”. If the RUT test 
demonstrated a positive test more than 4 
hours later and within 24 hours, it was 
marked as “late positive”. 
 
Results 
A total of 580 consecutive patients who 
performed an OGD at our centre were 
recruited. Thirty – eight (38) patients were 
excluded as 31 patients had been previously 
tested and/or treated for H. Pylori and 
another 7 patients did not have a CLO test 
taken during the OGD. From the 542 
eligible patients, 52.4% were female (284 
patients). 
The minimum age was 15 and the 
maximum was 88. The patient`s mean age 
was 54.64 years (median age: 58 years; 
range 15 - 88 years). Figure 1 demonstrates 
the age distribution of the patients’ cohort.  
The main clinical indication was 
dyspepsia (44.7%). Other main indications 
were gastro-oesophageal reflux disease 
(GORD) (24.5%) and in the investigation of 
anaemia (10.1%). The other clinical 
indications are demonstrated in Table 1.  
From the cohort, 85% of the RUTs 
were negative for H.pylori. The rest were 
positive and were classified into early 
positive (8.7%) and late positive (6.3%).  
Analysis of patients’ age with RUT 
positivity revealed that patients above the 
age of 60 years were more likely to have a 
positive result (p=0.013). Figure 2 
demonstrates the percentage of positive 
RUT tests for every age group. 
From the patients with a negative 
RUT test, 25.4% were smokers. Similarly 
from those with a positive result, 28.4% 
were smokers. There was no statistical 
significance between the H.pylori results 
and smoking (p=0.6). 
The most commonly prescribed 
regimens were omeprazole 20mg BD + 
Amoxicillin 1g BD + Clarithromycin 500mg 
BD for 10 days (33%) and 14 days (28%). 
In the rest (39%), 10 different regimens 
were prescribed, as can be demonstrated in 
Figure 3. 
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Figure 1: Age distribution of patients who underwent OGD 
The minimum age was 15 and the maximum was 88. The patient`s mean age was 54.64 years 
(median age: 58 years; range 15 - 88 years). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Clinical indication for OGD 
The main clinical indication was dyspepsia (44.7%). Other main indications were gastro-
oesophageal reflux disease (GORD) (24.5%) and in the investigation of anaemia (10.1%) 
 
Clinical Indication Percentage (%) 
Dyspepsia 44.7 
GORD 24.5 
Anaemia 10.1 
Weight loss 2.2 
Variceal Screening due to cirrhosis 2 
Dysphagia 1.1 
Not specified 3 
Screening for upper GI cancer 6.5 
Work-up for coeliac disease 2.2 
Suspected upper GI bleeding 2 
Gastric mass on CT scan and/or 
increased uptake on prior PET scan 
1.7 
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Figure 2: Percentage of Positive RUT in each age group 
From the cohort, 85% of the RUTs were negative for H.pylori. The rest were positive and were 
classified into early positive (8.7%) and late positive (6.3%).  Analysis of patients’ age with 
RUT positivity revealed that patients above the age of 60 years were more likely to have a 
positive result (p=0.013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
H. pylori infection is a cause of peptic 
ulcer disease, gastric mucosa-associated 
lymphoid tissue (MALT) lymphoma and 
gastric cancer. RUTs are used widely 
throughout the world in endoscopy units to 
determine if patients are infected with H. 
pylori. The accuracy of these tests is 
important because a missed diagnosis of H. 
pylori infection can thus result in various 
pathologies.15 
In the RUT, the gastric biopsy is put 
into a gel medium containing urea and a pH 
indicator. If present, the urease enzyme of 
H. pylori splits urea into ammonia and 
carbon dioxide. Ammonia alters the pH of 
the medium which then causes the colour 
change of the pH indicator. This process can 
take a variable amount of time and 
potentially there are various variables such 
as previous exposure to PPI`s, antibiotics 
and amount of urease that is produced by the 
bacterium.16 The expectation from a clinical 
perspective and also administrative is to 
provide a quick and reliable result before the 
patient leaves the endoscopy unit in view of 
patient satisfaction and as to decrease the 
need for phone calls on the next day and 
other related paperwork.  
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Figure 3: Treatment regimen prescribed to patients with a positive RUT 
The most commonly prescribed regimens were omeprazole 20mg BD + Amoxicillin 1g BD + 
Clarithromycin 500mg BD for 10 days (33%) and 14 days (28%). In the rest (39%), 10 
different regimens were prescribed 
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The overall prevalence of 15% does not 
support the empirical treatment for H. Pylori 
amongst symptomatic patients within our 
population. There was a statistically 
significant difference in prevalence between 
patients below and above the age of 60 years 
(p=0.013). Furthermore in patients under 
the age of 20 years, none of the patients had 
H. Pylori. One possible bias within the study 
group could have been that although patients 
were told to stop proton pump inhibitors 2 
weeks prior to the OGD, they might not 
have done so and they might have consumed 
antibiotics in the preceding 4 weeks. This 
would have led to an under representation of 
H.pylori. Similarly, we only tested for H. 
pylori with one modality (the RUT) and did 
not compare the result with histology and/or 
culture as a reference standard. This could 
also have led to a lower incidence.  
However, previous studies have 
demonstrated that the RUT is 97% specific 
and 98% sensitive when compared to 
histology which was 100% specific and 91% 
sensitive.16  Furthermore, previous data from 
studies has demonstrated that overall 
positivity is 75% within 20 minutes, 85% 
are detected at 1 hour, 90% by 3 hours and 
95% by 24 hours.17  Data from our study 
contrasts significantly with this data as 42% 
of the RUT turned positive after 4 hours. 
In view of this previous data and the 
costs involved, we did not check for 
H.pylori with other modalities. However, we 
assessed what really happens in the day-to-
day clinical practice. It is important to note 
that there is limited recent analysis about the 
timing of the colour change for this RUT 
and most data is coming from the late 1980s. 
Thus, in view of increasing or changing 
antibiotic resistance patterns it might be 
prime time to review this, as analysis of the 
RUT at an early stage and not reviewing at 
24 hours might lead to missing out on the 
diagnosis of H.pylori and thus not treating it.   
Previous studies have demonstrated both 
positive and negative associations of 
smoking with H.pylori.14 In this study there 
was no correlation between the presence of 
H.pylori and smoking. No H.pylori related 
malignancies were noted within this cohort. 
Inconsistencies regarding the 
eradication regimes prescribed in the 
endoscopy unit are evident and depend on 
consultant preference and the junior doctors 
who prescribe the treatment after checking 
RUT. As culture with antibiotic sensitivities 
is not routinely performed when H.pylori 
infection is diagnosed, it is generally 
recommended that different antibiotics be 
given at higher doses for 14 days. 18 Our 
study concluded that only 28% of the 
positive RUT patients were prescribed such 
a regime. 
Increased antibiotic resistance is a 
recognised problem affecting the overall 
success rate of eradication of H.pylori. To 
minimise the clinical impact of 
antimicrobial resistance and eradication 
failure, several studies recommend 
antimicrobial susceptibility testing prior to 
initiating treatment. 19,20  Ideally antibiotic 
choice should be based on culture and 
sensitivity of each H.pylori strain cultured in 
the biopsy however this is not practiced at 
Mater Dei Hospital and the eradication 
therapy is chosen empirically.  
The difficulties associated with 
performing culture and antibiotic sensitivity 
studies for H.pylori include both expense 
and the fastidiousness of the organism. 
Studies have shown that the use of a single 
antral biopsy for assessing efficacy of a 
particular treatment regimen may fail to 
detect resistant strains. 21  Thus resistance 
variability of H.pylori organisms at different 
gastric mucosal sites is a contributing factor 
to higher eradication rates and such 
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antibiotic resistance would require multiple 
gastric biopsies from different sites.  
Limitations to this study which may 
have affected the  positivity rate of the RUT 
and thus the outcome of the study is that 
there is no recorded data of how many 
biopsies and from where they were taken 
and used for each RUT, although it is 
standard practice to take at least one sample 
from the antrum of the stomach.  
Another possible limitation to the study 
is that there is no available follow up on 
successful eradication of H. Pylori though 
this was not one of the intended aims of the 
study as this  is not routine practice at Mater 
Dei Hospital but the choice of the respective 
endoscopist. 
 
Conclusion 
This study demonstrates that various 
regimens are used in clinical practice. 
However, we have to note the increasing 
antibiotic resistance. Various eradications 
rates have been ascribed to different 
regimens. In view of the relatively low 
prevalence of H.pylori, especially amongst 
young patients, antimicrobial resistance 
studies of H.pylori should be actively 
considered as to have better guidance with 
regards to antibiotic prescription. 
Furthermore, the significant increase in 
positivity post- 4 hours necessitate that if the 
test is still negative at 4 hours, it has to be 
re-analysed at 24 hours.  
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